Shimizu, Hirotaka http://orcid.org/0000-0001-7173-0420
Ebana, Ryo
Kudo, Takahiro
Sato, Takuro
Hara, Tomoko
Hosoi, Kenji
Usami, Masaaki
Yoshida, Masashi
Takeuchi, Ichiro
Nakase, Hiroshi
Iwama, Itaru
Arai, Katsuhiro
Shimizu, Toshiaki
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (No. 2019A-3, Health, Labour Sciences Research Grants for studies on intractable diseases (No.20FC1037))
Article History
Received: 10 November 2021
Accepted: 25 January 2022
First Online: 14 February 2022
Declarations
:
: Hiroshi Nakase has received support from AbbVie GK., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co.,Ltd., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co.,Ltd., Pfizer Inc, Celgene Corporation., EA Pharma Co.,Ltd., Zeria Pharmaceutical CO.,Ltd., Mochida Pharmaceutical Co.,Ltd., Nippon Kayaku Co.,Ltd., Daiichi Sankyo Company, Limited., JIMRO Co.,Ltd., as well as grants for commissioned/joint research from Hoya Group Pentax Medical, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, AbbVie GK., Mochida Pharmaceutical Co.,Ltd. Katsuhiro Arai received honoraria for consulting and lecture from EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and a research grant from AstraZeneca K.K. Toshiaki Shimizu is an endowed chair of Taiko Pharmaceutical and has received a research grant from the Food Science Institute Foundation and a scholarship grant from JCR Pharmaceuticals Co., Ltd. Other authors declare that they have no conflict of interests.